Penumbra Inc. (PEN)
270.28
1.61 (0.60%)
At close: Feb 18, 2025, 3:59 PM
294.00
8.78%
After-hours: Feb 18, 2025, 07:29 PM EST
undefined% (undefined)
| Bid | 293.9 |
| Market Cap | 10.37B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0.86 |
| PE Ratio (ttm) | 314.28 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 295 |
| Volume | 547,155 |
| Avg. Volume (20D) | 385,918 |
| Open | 266.50 |
| Previous Close | 268.67 |
| Day's Range | 264.81 - 273.56 |
| 52-Week Range | 148.00 - 277.89 |
| Beta | undefined |
About PEN
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling...
Industry Medical - Devices
Sector Healthcare
IPO Date Sep 18, 2015
Employees 4,200
Stock Exchange NYSE
Ticker Symbol PEN
Website https://www.penumbrainc.com
Analyst Forecast
According to 15 analyst ratings, the average rating for PEN stock is "Buy." The 12-month stock price forecast is $266.5, which is a decrease of -1.40% from the latest price.
Buy 73.33%
Hold 26.67%
Sell 0.00%
Next Earnings Release
Penumbra Inc. is scheduled to release its earnings on May 6, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 day ago
+0.92%
Penumbra shares are trading higher after the compa...
Unlock content with
Pro Subscription
2 months ago
+4.7%
Penumbra shares are trading higher after Wells Fargo upgraded the stock from Equal-Weight to Overweight and raised its price target from $190 to $275.
